來凱(2105.HK)將在2025美國糖尿病協會年會上展示多項ActRII領域自主研發成果
2025年5月27日——來凱醫藥(2105.HK)今日宣佈,公司將在美國糖尿病協會(American Diabetes Association, ADA)第85屆科學年會上,以壁報形式展示多項增肌減脂領域的研發成果——靶向ActRII的三款單克隆抗體LAE102、LAE103和LAE123的臨牀前數據,以及其中一款針對ActRIIA的單抗LAE102的首次人體研究數據。
ADA科學年會是全球糖尿病領域的頂級學術盛會,將於今年6月20日-23日在美國芝加哥召開。
LAE102是來凱醫藥自主研發的一種ActRIIA單克隆抗體,在臨牀前模型中已顯示出增加肌肉並減少脂肪的效果。在已完成的中國I期臨牀試驗單劑量遞增研究(SAD研究)中,單次劑量的LAE102給藥導致激活素A水平顯著且持續增加,表明了強有力的靶點抑制。這項研究的詳細數據將於本次ADA會議上披露。此外,來凱與禮來合作在美國快速推進LAE102肥胖症治療的臨牀研究。
來凱圍繞ActRII通路的自主研發深入佈局,其中已進入IND支持性研究階段的LAE103(ActRIIB選擇性抗體)和LAE123(針對ActRIIA/IIB雙靶點抑制劑),將探索臨牀用於肌肉及危重疾病領域的創新療法。
壁報一
摘要編號:861-P
摘要標題:靶向ActRII——開發單克隆抗體LAE102、LAE103和LAE123作為增肌減脂候選療法
展示時間:2025年6月22日(星期日)12:30 PM – 13:30 PM(美國中部時間)
展示地點:
美國伊利諾伊州芝加哥McCormick Place會議中心Poster Hall (Hall F1)
壁報二
摘要編號:2205-LB
摘要標題:LAE102的首次人體研究:在健康志願者中評估其安全性、耐受性、藥代動力學和藥效學
展示時間:2025年6月22日(星期日)12:30 PM – 13:30 PM(美國中部時間)
展示地點:
美國伊利諾伊州芝加哥McCormick Place會議中心Poster Hall (Hall F1)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.